Your browser doesn't support javascript.
loading
Cord blood maternal microchimerism following unrelated cord blood transplantation.
Kanaan, Sami B; Delaney, Colleen; Milano, Filippo; Scaradavou, Andromachi; Besien, Koen van; Allen, Judy; Lambert, Nathalie C; Cousin, Emma; Thur, Laurel A; Kahn, Elena; Forsyth, Alexandra M; Sensoy, Oyku; Nelson, J Lee.
Afiliación
  • Kanaan SB; Clinical Research Division, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA. skanaan@fredhutch.org.
  • Delaney C; Clinical Research Division, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA.
  • Milano F; Department of Medicine, University of Washington (UW), Seattle, WA, USA.
  • Scaradavou A; Clinical Research Division, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA.
  • Besien KV; Department of Medicine, University of Washington (UW), Seattle, WA, USA.
  • Allen J; Stem Cell Transplantation and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Lambert NC; Division of Hematology/Oncology, Weill Cornell Medical College, New York, NY, USA.
  • Cousin E; Clinical Research Division, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA.
  • Thur LA; INSERM UMRs 1097 Arthrites Autoimmunes, Aix Marseille University, Marseille, France.
  • Kahn E; Clinical Research Division, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA.
  • Forsyth AM; Clinical Research Division, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA.
  • Sensoy O; Clinical Research Division, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA.
  • Nelson JL; Clinical Research Division, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA.
Bone Marrow Transplant ; 56(5): 1090-1098, 2021 05.
Article en En | MEDLINE | ID: mdl-33257776
Cord blood transplantation (CBT) is associated with low risk of leukemia relapse. Mechanisms underlying antileukemia benefit of CBT are not well understood, however a previous study strongly but indirectly implicated cells from the mother of the cord blood (CB) donor. A fetus acquires a small number of maternal cells referred to as maternal microchimerism (MMc) and MMc is sometimes detectable in CB. From a series of 95 patients who underwent double or single CBT at our center, we obtained or generated HLA-genotyping of CB mothers in 68. We employed a technique of highly sensitive HLA-specific quantitative-PCR assays targeting polymorphisms unique to the CB mother to assay CB-MMc in patients post-CBT. After additional exclusion criteria, CB-MMc was evaluated at multiple timepoints in 36 patients (529 specimens). CB-MMc was present in seven (19.4%) patients in bone marrow, peripheral blood, innate and adaptive immune cell subsets, and was detected up to 1-year post-CBT. Statistical trends to lower relapse, mortality, and treatment failure were observed for patients with vs. without CB-MMc post-CBT. Our study provides proof-of-concept that maternal cells of the CB graft can be tracked in recipients post-CBT, and underscore the importance of further investigating CB-MMc in sustained remission from leukemia following CBT.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia / Trasplante de Células Madre Hematopoyéticas / Trasplante de Células Madre de Sangre del Cordón Umbilical Límite: Female / Humans Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia / Trasplante de Células Madre Hematopoyéticas / Trasplante de Células Madre de Sangre del Cordón Umbilical Límite: Female / Humans Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido